Skip to main content

Zura Bio Ltd

For the period ended Mar 31, 2025. Filed May 8, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

ZURA$1.24-69.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(In thousands, except share data)

​​​​​​​
​ · March 31, · December 31,
​ · ​ · 2025 · ​ · 2024
​ · ​ · (unaudited) · ​ · ​ · ​
Assets​​​​​​
Current assets · ​ · ​ · ​ · ​
Cash and cash equivalents​$170,569​$176,498
Prepaid expenses and other current assets​​1,123​​2,246
Total current assets​​171,692​​178,744
Property and equipment, net​​106​​91
Other assets​​698​​698
Total assets​$172,496​$179,533
​​​​​​​
Liabilities, Redeemable Noncontrolling Interest and Shareholders’ Equity​​​​​​
Current liabilities​​​​​​
Accounts payable and accrued expenses​$21,092​$19,514
Total current liabilities​​21,092​​19,514
Total liabilities​​21,092​​19,514
​​​​​​​
Commitments and contingencies (Note 9)​​​​​​
​​​​​​​
Redeemable noncontrolling interest​​11,663​​11,663
​​​​​​​
Shareholders’ Equity​​​​​​
Preferred shares, $0.0001 par value, 1,000,000 authorized as of March 31, 2025 and December 31, 2024; no shares issued and outstanding as of March 31 2025 and December 31, 2024​​—​​—
Class A Ordinary Shares, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 68,374,998 and 65,297,530 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively​​7​​7
Additional paid-in capital​​311,532​​302,705
Accumulated deficit​​(173,339)​​(155,897)
Total Zura Bio Limited shareholders’ equity​​138,200​​146,815
Noncontrolling interest​​1,541​​1,541
Total shareholders’ equity​​139,741​​148,356
Total liabilities, redeemable noncontrolling interest and shareholders’ equity​$172,496​$179,533
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.